Haematology and Leukaemia PhD / MPhil / MD
Program Overview
The Liverpool Cancer Research UK Centre focuses on haemato-oncology research, particularly Chronic Myeloid Leukemia and lymphoproliferative disorders. Led by Professor Andrew Pettitt, the program includes research interests in cell signalling, disease biology, and translational work for the development of novel therapies. Postgraduate students have access to taught modules, a wide range of development opportunities, and world-class facilities for Biomedical Imaging, Drug Safety Science, and Clinical Trials Research.
Program Outline
Haemato-oncology is one of Liverpool’s recognised strengths with scientific expertise in Chronic Myeloid Leukemia (CML) and lymphoproliferative disorders and strong clinical leadership that includes chairmanship of the National Cancer Research Institute (NCRI) Haematological Oncology CSG and CML Subgroup and membership of the Lymphoma CSG and Subgroups for Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML), High Grade Non-Hodgkin's Lymphomas (HG-NHL) and Low Grade Non-Hodgkin's Lymphomas (LG-NHL). Professor Andrew Pettitt leads a large programme of clinical and translational research focussed on lymphoid malignancy with strong links with industry and national collaborative groups in lymphoma and haematological oncology.
Other:
Our research interests Clinical studies conducted with the intent to advance therapies to the clinic or develop principles for application of therapeutics to human disease Non-human or non-clinical studies conducted with the intent to advance therapies to the clinic or develop principles for application of therapeutics to human disease Any clinical trial of a therapy that was initiated based on the above. Research themesOur research themes include: In Chronic Lymphocyte Leukeamia (CLL) Protein Kinase C (PKC) and c-abl in B-cell receptor signalling have been found to be important in the selection and perpetuation of the malignant clone In hairy cells constitutive PKC-dependent ERK activation has been identified as central to malignant cell survival and oxidant production by NOX-5 has been shown to be of importance in constitutive activation Current work is focused on defining CLL subgroups on the basis of signalling profiles, on the control of adhesion-receptor expression in CLL and on the oncogenic origin of the constitutive signals of hairy cells Translational work has identified Akt and Hsp90 as worthy molecular targets for novel therapy The Clinical Trials Advisory and Awards Committee (CTAAC) -funded PACIFIC [RiChFlo] phase III trial will compare two different induction regimens for follicular lymphoma. To address this problem, a novel prognostic test has been developed that probes the functional integrity of the ATM-p53-p21 pathway The Liverpool Leukaemia Bank houses >27,000 vials of viable CLL cells obtained from >400 patients. The group also hosts the Leukaemia Research Fund-funded UK CLL Trials Biobank Training PhD students can take taught modules - on either a formal basis with exams taken and a record of completion generated or less formally. Commonly, students use the opportunity to upskill in areas like bioinformatics and statistics, but modules on defined areas of biology are also available. A wide variety of further development opportunities are available from the PGR Development Hub. FacilitiesThe Institutes research infrastructure is designed to give researchers access to world class facilities in the best possible environment. The departments of the Institute have the following facilities and resources: Biomedical Imaging Centre for Antimicrobial Pharmacodynamics Centre for Drug Safety Science Health Data Science Network Centre for Preclinical Imaging Clinical Trials Research Centre Harris-Wellbeing Preterm Birth Research Centre Liverpool Bio-Innovation Hub (LBIH) Biobank Liverpool Cancer Trials Unit MRC North West Hub for Trials Methodology Research North West Cancer Research Centre – University of Liverpool Pancreas Biomedical Research Unit Wolfson Centre for Personalised Medicine. Postgraduate researchers also benefit from flexible access to world-class equipment and expertise through the Shared Research Facilities.
|-----------------------------------| | UK students | £4,786 | | Faculty of Health and Life Sciences | £29,750 (Band A)^ | | Faculty of Science and Engineering | £29,750 (Band A)^ or £23,400 (Band B) | | Faculty of Humanities and Social Sciences | £23,400 (Band B) | | Part time | £2,393 | | Faculty of Health and Life Sciences | £14,900 (Band A)^ | | Faculty of Science and Engineering | £14,900 (Band A)^ or £11,700 (Band B) | | Faculty of Humanities and Social Sciences | £11,700 (Band B) | |^ Self-funded, full-time international students studying a PhD programme classified as Band A will receive a £2,000 reduction in their fees for the first year only. |
